Bobak Azamian
Principal executive officer pay for Bobak Azamian, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Tarsus Pharmaceuticals, Inc. (TARS) FY2023–FY2025
Beat peersTSR 304% vs peer group 33% over FY2023–FY2025
Turnaround$100 invested moved from behind the peer group ($90.00 vs $94.01) to ahead ($363.91 vs $124.72) over FY2023–FY2025
Aligned: paid up as stock roseCAP $4,499,232→$31,092,283 while $100 invested went $90.00→$363.91
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $3.1M | $4.5M |
| FY2024 | $7.9M | $19.8M |
| FY2025 | $6.6M | $31.1M |
The company's "$100 invested" index ran $90.00 at FY2023 → $363.91 by FY2025 — an annualized return of 101.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 101.1%/yr at TARS ( FY2023–FY2025). See the CEO track-record ranking for context.